Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306134 | 0.90 | CUL4A (0.45) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A | |
| SCHEMBL810412 | 0.88 | ALDH1A1 (0.43) | KMT2AMAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL24453320 | 0.84 | POLB (0.45) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A | |
| SCHEMBL16217686 | 0.82 | KMT2A (0.39) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A | |
| SCHEMBL8367665 | 0.81 | ALDH1A1 (0.43) | KMT2AMAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL28614706 | 0.79 | MAPT (0.41) | KMT2AMAPTALDH1A1LMNAMEN1 | |
| SCHEMBL31047098 | 0.79 | CUL4A (0.45) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A | |
| SCHEMBL4306866 | 0.79 | ALDH1A1 (0.47) | KMT2AMAPTALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3106685 | 0.79 | CUL4A (0.45) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A | |
| SCHEMBL810673 | 0.79 | CUL4A (0.45) | KMT2AMAPTALDH1A1SMN1; SMN2CUL4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1539133-B1 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| EP-1549156-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | Investigacion Y Nutricion, S.L. (ES) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004014361-A9 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004014150-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | INVESTIGACION Y NUTRICION, S.L. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | KMT2A 1059/4885MAPT 4083/4885ALDH1A1 3450/4885 |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | KMT2A 1485/4885MAPT 825/4885ALDH1A1 909/4885 |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | QARS1, NQO2, AAAS | KMT2A 2688/4885MAPT 4662/4885ALDH1A1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.